BIM-26226

BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC50 = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC50 values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth[1][2][3][4].

Product Specifications

CAS Number

[136207-23-3]

UNSPSC

12352209

Target

Bombesin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bim-26226.html

Purity

99.62

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)C[C@@H](C(OC)=O)NC([C@H](CC1=CNC=N1)NC([C@@H](C)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC2=CNC3=CC=CC=C23)NC([C@H](CCC(N)=O)NC([C@@H](CC4=C(F)C(F)=C(F)C(F)=C4F)N)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C49H63F5N12O10

Molecular Weight

1075.09

References & Citations

[1]Dietrich JB, et, al. Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells. Regul Pept. 1994 Oct 21;53 (3) :165-73. |[2]Damgé C, et, al. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347 (1) :77-86.|[3]Gouyon B, et al. In-vivo effect of somatostatin analog, lanreotide, and/or grp antagonist, bim-26226, on the growth of colon-cancer peritoneal carcinomatosis in the rat. Int J Oncol. 1995 Nov;7 (5) :1167-73.|[4]Bold RJ, et al. Bombesin stimulates the in vitro growth of a human gastric cancer cell line. J Cell Physiol. 1994 Dec;161 (3) :519-25.